trial
as of 2026-07-01Study of ALTO-101 in Patients With Schizophrenia
NCTId NCT06502964
at a glance
Phase 2 · Recruiting
Enrollment 82 (estimated)
Sponsored by Alto Neuroscience
Primary completion 2026-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Recruiting
Enrollment
82 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2024-06-11
Primary completion
2026-02
Eligibility
ALL · 21 Years · 55 Years
Interventions & indications
Sponsors
Alto NeuroscienceLead Sponsor
Sites
14 total
Garden Grove, United StatesLos Angeles, United StatesOrange, United StatesWalnut Creek, United StatesHollywood, United StatesTampa, United StatesSnellville, United StatesChicago, United StatesGaithersburg, United StatesBelmont, United StatesNew York, United StatesNew York, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
82
Phase
PHASE2
Primary Completion Date
2026-02
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
indication